Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, protein-synthesis inhibitors, tetracycline derivatives	2661	220620-09-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: CL-331002 CL 331002 tigecycline tygacil glycylcycline	Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, tigecycline has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila. Molecular weight: 585.66 Formula: C29H39N5O8 CLOGP: -0.19 LIPINSKI: 3 HAC: 13 HDO: 7 TPSA: 205.76 ALOGS: -3.11 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

CL-331002
CL 331002
tigecycline
tygacil
glycylcycline

Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic; however, tigecycline has demonstrated bactericidal activity against isolates of S. pneumoniae and L. pneumophila.

Molecular weight: 585.66
Formula: C29H39N5O8
CLOGP: -0.19
LIPINSKI: 3
HAC: 13
HDO: 7
TPSA: 205.76
ALOGS: -3.11
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.45 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	22 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	12 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.20 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	48 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK7,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PLK1,PLK2,PLK3,PLK4,PRKCD,PRKDC,PTK2,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70	69
kinase-selectivity-class	AXL,CDK4,EIF2AK3,EPHB4,GRK2,MAP2K6,MAPK7,STK33,TEK	9
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
June 15, 2005	FDA	PF PRISM CV

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pathogen resistance	262.24	29.61	68	5919	8047	90614413
Pancreatitis acute	205.76	29.61	78	5909	32037	90590423
Drug resistance	195.23	29.61	74	5913	30375	90592085
Blood fibrinogen decreased	154.98	29.61	31	5956	1139	90621321
Coagulopathy	147.08	29.61	56	5931	23233	90599227
Hypofibrinogenaemia	132.72	29.61	28	5959	1342	90621118
Pancreatitis	122.63	29.61	69	5918	69757	90552703
Thrombocytopenia	100.76	29.61	94	5893	208631	90413829
Dysbiosis	99.54	29.61	23	5964	1679	90620781
Multiple organ dysfunction syndrome	84.73	29.61	54	5933	68282	90554178
Drug ineffective	72.40	29.61	227	5760	1384071	89238389
Systemic inflammatory response syndrome	68.98	29.61	23	5964	6493	90615967
Off label use	66.21	29.61	190	5797	1102062	89520398
Septic shock	65.55	29.61	50	5937	84110	90538350
Multiple-drug resistance	61.21	29.61	22	5965	7754	90614706
Paraspinal abscess	59.50	29.61	11	5976	264	90622196
Sepsis	59.31	29.61	66	5921	179748	90442712
Lipase increased	57.00	29.61	23	5964	11088	90611372
Escherichia infection	55.35	29.61	25	5962	15870	90606590
Klebsiella infection	55.20	29.61	22	5965	10275	90612185
Mitochondrial toxicity	49.84	29.61	11	5976	652	90621808
Mycobacterium abscessus infection	49.64	29.61	12	5975	1063	90621397
Pain	48.24	29.61	5	5982	996336	89626124
Hepatic failure	48.23	29.61	31	5956	39697	90582763
Acinetobacter infection	46.75	29.61	13	5974	1995	90620465
Nausea	46.19	29.61	169	5818	1110147	89512313
Haemodynamic instability	45.81	29.61	20	5967	11719	90610741
Graft versus host disease in gastrointestinal tract	44.50	29.61	15	5972	4373	90618087
Vomiting	44.34	29.61	133	5854	788160	89834300
Nephropathy toxic	44.31	29.61	20	5967	12668	90609792
Coagulation time prolonged	44.25	29.61	12	5975	1678	90620782
Tonsillitis bacterial	44.20	29.61	8	5979	170	90622290
Abscess	42.41	29.61	22	5965	18869	90603591
Morganella infection	42.29	29.61	10	5977	806	90621654
Adjusted calcium decreased	42.22	29.61	8	5979	220	90622240
Deafness	41.51	29.61	23	5964	22491	90599969
Biloma	41.36	29.61	7	5980	99	90622361
Platelet count decreased	41.27	29.61	48	5939	136921	90485539
Arthralgia	40.10	29.61	3	5984	778519	89843941
Blood urea increased	40.08	29.61	25	5962	30388	90592072
Coma hepatic	38.94	29.61	9	5978	657	90621803
Graft versus host disease	38.84	29.61	16	5971	8128	90614332
Blood bilirubin increased	38.69	29.61	28	5959	43442	90579018
Haemostasis	38.06	29.61	8	5979	376	90622084
Globulins decreased	37.54	29.61	8	5979	402	90622058
Renal failure	36.31	29.61	44	5943	130963	90491497
Immunosuppressant drug level increased	35.93	29.61	13	5974	4667	90617793
Headache	35.53	29.61	7	5980	862739	89759721
Bacterial sepsis	35.20	29.61	13	5974	4942	90617518
Hepatotoxicity	35.15	29.61	27	5960	45815	90576645
Graft versus host disease in skin	34.51	29.61	12	5975	3841	90618619
Acute kidney injury	33.90	29.61	69	5918	320318	90302142
Wound haemorrhage	33.88	29.61	11	5976	2856	90619604
Ototoxicity	33.59	29.61	10	5977	1954	90620506
Respiratory failure	33.18	29.61	40	5947	118378	90504082
Enterococcal infection	32.53	29.61	15	5972	9976	90612484
Agranulocytosis	29.91	29.61	22	5965	34980	90587480

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coagulopathy	238.02	27.15	105	7956	22057	42591217
Pathogen resistance	225.87	27.15	84	7977	11366	42601908
Drug resistance	214.39	27.15	112	7949	34136	42579138
Off label use	184.28	27.15	383	7678	637952	41975322
Drug ineffective	173.49	27.15	371	7690	629826	41983448
Septic shock	172.81	27.15	141	7920	91531	42521743
Hypofibrinogenaemia	166.50	27.15	44	8017	1923	42611351
Blood fibrinogen decreased	155.69	27.15	40	8021	1563	42611711
Klebsiella infection	106.63	27.15	49	8012	11283	42601991
Enterococcal infection	91.66	27.15	45	8016	11994	42601280
Multiple organ dysfunction syndrome	90.02	27.15	101	7960	96934	42516340
Coagulation time prolonged	83.93	27.15	24	8037	1408	42611866
Treatment failure	83.04	27.15	79	7982	62545	42550729
Ototoxicity	76.49	27.15	25	8036	2300	42610974
Pancreatitis acute	74.62	27.15	57	8004	33507	42579767
Drug reaction with eosinophilia and systemic symptoms	71.37	27.15	61	8000	42014	42571260
Sepsis	67.91	27.15	129	7932	199205	42414069
Mycobacterium chelonae infection	65.72	27.15	19	8042	1159	42612115
Thrombocytopenia	64.63	27.15	123	7938	190156	42423118
Dysbiosis	58.72	27.15	16	8045	785	42612489
Deafness neurosensory	57.78	27.15	23	8038	3723	42609551
Platelet count decreased	56.45	27.15	97	7964	138484	42474790
Nausea	49.71	27.15	176	7885	396623	42216651
Clostridium difficile colitis	49.22	27.15	37	8024	21215	42592059
Blood bilirubin increased	44.36	27.15	47	8014	42205	42571069
Trichosporon infection	42.82	27.15	13	8048	939	42612335
Pancreatitis	41.69	27.15	46	8015	43222	42570052
Liver injury	41.40	27.15	32	8029	19116	42594158
Drug ineffective for unapproved indication	39.26	27.15	46	8015	46117	42567157
Lipase increased	37.69	27.15	24	8037	10542	42602732
Fatigue	37.27	27.15	18	8043	435623	42177651
Gallstone ileus	36.20	27.15	6	8055	22	42613252
Pseudomonas infection	35.27	27.15	27	8034	15896	42597378
Fungaemia	34.06	27.15	15	8046	3121	42610153
Candida infection	33.93	27.15	30	8031	21580	42591694
Activated partial thromboplastin time prolonged	33.12	27.15	26	8035	15877	42597397
Staphylococcal infection	32.82	27.15	38	8023	37605	42575669
Bilirubin conjugated increased	31.78	27.15	15	8046	3662	42609612
Myasthenia gravis crisis	31.52	27.15	10	8051	836	42612438
Acoustic neuroma	31.50	27.15	7	8054	145	42613129
Acinetobacter test positive	31.41	27.15	7	8054	147	42613127
Bacterial infection	31.02	27.15	32	8029	27847	42585427
Fall	30.83	27.15	4	8057	234516	42378758
Pain	30.29	27.15	5	8056	244843	42368431
Dizziness	28.88	27.15	6	8055	249248	42364026
Flavobacterium infection	28.35	27.15	6	8055	98	42613176
Megacolon	28.33	27.15	12	8049	2273	42611001
Product use in unapproved indication	27.56	27.15	87	7974	184369	42428905

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pathogen resistance	411.14	24.08	130	12800	17542	110558827
Coagulopathy	410.85	24.08	161	12769	40750	110535619
Drug resistance	345.06	24.08	156	12774	56218	110520151
Blood fibrinogen decreased	314.68	24.08	71	12859	2604	110573765
Off label use	250.20	24.08	542	12388	1499643	109076726
Drug ineffective	240.65	24.08	538	12392	1520002	109056367
Pancreatitis acute	236.29	24.08	123	12807	60151	110516218
Septic shock	233.86	24.08	173	12757	157355	110419014
Hypofibrinogenaemia	222.87	24.08	53	12877	2454	110573915
Dysbiosis	153.32	24.08	38	12892	2094	110574275
Multiple organ dysfunction syndrome	147.17	24.08	130	12800	151580	110424789
Thrombocytopenia	147.10	24.08	192	12738	348693	110227676
Klebsiella infection	143.67	24.08	62	12868	19947	110556422
Coagulation time prolonged	132.12	24.08	36	12894	2881	110573488
Sepsis	126.96	24.08	173	12757	327173	110249196
Platelet count decreased	114.85	24.08	138	12792	230305	110346064
Enterococcal infection	107.75	24.08	51	12879	20315	110556054
Drug reaction with eosinophilia and systemic symptoms	99.42	24.08	80	12850	82015	110494354
Pancreatitis	96.36	24.08	83	12847	93450	110482919
Acinetobacter infection	94.41	24.08	29	12901	3544	110572825
Multiple-drug resistance	85.24	24.08	38	12892	13197	110563172
Lipase increased	84.44	24.08	42	12888	18630	110557739
Pain	82.98	24.08	8	12922	954947	109621422
Mycobacterium chelonae infection	73.14	24.08	23	12907	3037	110573332
Pseudomonas infection	68.71	24.08	42	12888	27811	110548558
Blood bilirubin increased	65.52	24.08	61	12869	75911	110500458
Activated partial thromboplastin time prolonged	63.70	24.08	37	12893	22331	110554038
Clostridium difficile colitis	62.40	24.08	47	12883	43731	110532638
Ototoxicity	58.72	24.08	21	12909	4110	110572259
Blood urea increased	57.04	24.08	49	12881	54908	110521461
Hepatotoxicity	56.79	24.08	52	12878	63348	110513021
Hepatic failure	55.09	24.08	53	12877	68686	110507683
Headache	54.02	24.08	18	12912	882359	109694010
Escherichia infection	51.41	24.08	33	12897	23783	110552586
Treatment failure	49.86	24.08	104	12826	277130	110299239
Paraspinal abscess	48.43	24.08	11	12919	415	110575954
Prothrombin time prolonged	47.69	24.08	28	12902	17233	110559136
Deafness neurosensory	47.56	24.08	23	12907	9596	110566773
Fall	47.54	24.08	7	12923	603475	109972894
Nephropathy toxic	47.12	24.08	33	12897	27445	110548924
Systemic inflammatory response syndrome	46.47	24.08	25	12905	13018	110563351
Arthralgia	45.82	24.08	17	12913	779615	109796754
Mycobacterium abscessus infection	45.72	24.08	14	12916	1692	110574677
Trichosporon infection	44.99	24.08	13	12917	1287	110575082
Drug ineffective for unapproved indication	43.80	24.08	57	12873	102781	110473588
Renal failure	41.90	24.08	86	12844	226488	110349881
Amylase increased	41.84	24.08	23	12907	12496	110563873
Haemodynamic instability	40.44	24.08	28	12902	22860	110553509
Joint swelling	40.32	24.08	3	12927	442842	110133527
Abscess	40.27	24.08	30	12900	27439	110548930
Bacterial sepsis	40.01	24.08	21	12909	10405	110565964
Morganella infection	39.89	24.08	12	12918	1367	110575002
Renal impairment	39.01	24.08	75	12855	188370	110387999
Acute kidney injury	38.88	24.08	162	12768	635268	109941101
Tonsillitis bacterial	37.02	24.08	8	12922	239	110576130
Adjusted calcium decreased	36.71	24.08	8	12922	249	110576120
Product use in unapproved indication	35.54	24.08	124	12806	447253	110129116
Nausea	34.83	24.08	255	12675	1235435	109340934
Cholestasis	34.31	24.08	40	12890	64478	110511891
Drug-induced liver injury	34.21	24.08	55	12875	120012	110456357
Coma hepatic	33.88	24.08	10	12920	1067	110575302
Procalcitonin increased	33.87	24.08	14	12916	4042	110572327
Eosinophilic pneumonia acute	33.58	24.08	11	12919	1654	110574715
Staphylococcal infection	33.32	24.08	41	12889	69903	110506466
Respiratory failure	33.24	24.08	76	12854	215256	110361113
Candida infection	32.89	24.08	34	12896	47975	110528394
Electrocardiogram QT prolonged	32.54	24.08	51	12879	108909	110467460
Fatigue	32.44	24.08	58	12872	1215900	109360469
Immunosuppressant drug level increased	32.34	24.08	19	12911	11705	110564664
Transaminases increased	31.56	24.08	38	12892	63352	110513017
Graft versus host disease in gastrointestinal tract	31.42	24.08	17	12913	8951	110567418
Klebsiella bacteraemia	31.41	24.08	14	12916	4855	110571514
Biloma	31.33	24.08	7	12923	245	110576124
Pneumonia pseudomonal	31.26	24.08	16	12914	7530	110568839
Hepatic function abnormal	31.23	24.08	45	12885	89250	110487119
Peripheral swelling	31.08	24.08	5	12925	404029	110172340
Aspergillus infection	31.06	24.08	25	12905	25591	110550778
Haemostasis	30.57	24.08	8	12922	548	110575821
Acinetobacter test positive	30.27	24.08	7	12923	286	110576083
Mitochondrial toxicity	29.83	24.08	12	12918	3233	110573136
Acoustic neuroma	29.70	24.08	7	12923	311	110576058
Dizziness	29.63	24.08	23	12907	698170	109878199
Flavobacterium infection	29.62	24.08	6	12924	130	110576239
Alopecia	29.24	24.08	4	12926	364749	110211620
Agranulocytosis	29.09	24.08	36	12894	61724	110514645
Thrombin time prolonged	29.04	24.08	7	12923	343	110576026
Stenotrophomonas infection	28.94	24.08	14	12916	5844	110570525
Myasthenia gravis crisis	28.75	24.08	10	12920	1804	110574565
Fungaemia	28.43	24.08	14	12916	6072	110570297
Bilirubin conjugated increased	28.13	24.08	14	12916	6210	110570159
Globulins decreased	28.00	24.08	8	12922	761	110575608
Hepatitis cholestatic	27.59	24.08	20	12910	17546	110558823
Pneumonia klebsiella	27.29	24.08	14	12916	6618	110569751
Hypertriglyceridaemia	26.76	24.08	19	12911	16135	110560234
Depression	26.60	24.08	3	12927	317332	110259037
Megacolon	26.57	24.08	12	12918	4293	110572076
Pain in extremity	26.34	24.08	12	12918	487106	110089263
Deafness	26.06	24.08	23	12907	26686	110549683
Abdominal infection	25.48	24.08	12	12918	4719	110571650
Wound haemorrhage	25.47	24.08	12	12918	4726	110571643
Acute hepatic failure	25.29	24.08	26	12904	36442	110539927
Blood alkaline phosphatase increased	25.17	24.08	36	12894	70899	110505470
Endocarditis	25.14	24.08	17	12913	13354	110563015
Gallstone ileus	24.73	24.08	4	12926	22	110576347
Product dose omission issue	24.70	24.08	4	12926	321778	110254591
Penile oedema	24.47	24.08	6	12924	316	110576053
Geotrichum infection	24.41	24.08	8	12922	1204	110575165
Alanine aminotransferase increased	24.20	24.08	61	12869	183712	110392657

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01AA12	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines
FDA CS	M0021223	Tetracyclines
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175938	Tetracycline-class Antibacterial
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35441	antiinfective agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:36047	antibacterial drug

Related Drugs by ATC class:

J01AA Tetracyclines 13 drugs

chlortetracycline clomocycline demeclocycline doxycycline lymecycline metacycline minocycline omadacycline oxytetracycline penimepicycline rolitetracycline sarecycline show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pneumonia due to Streptococcus	indication	34020007
Haemophilus influenzae pneumonia	indication	70036007
Abdominal abscess	indication	75100008
Infectious disease of abdomen	indication	128070006
Complicated appendicitis	indication	418171008
Complicated Skin and Skin Structure E. Coli Infection	indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection	indication
Complicated Skin and Skin Structure Infection	indication
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection	indication
Legionella Pneumophila Pneumonia	indication
Complicated Bacterial Peritonitis	indication
Complicated Skin and Skin Structure Enterococcus Faecalis Infection	indication
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection	indication
Hyperbilirubinemia	contraindication	14783006	DOID:2741
Gastrointestinal perforation	contraindication	51875005
Hepatic failure	contraindication	59927004
Pancreatitis	contraindication	75694006	DOID:4989
Pregnancy, function	contraindication	289908002
Pseudomembranous enterocolitis	contraindication	397683000
Antibiotic-Induced Hypoprothrombinemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.13	acidic
pKa2	8.64	acidic
pKa3	11.14	acidic
pKa4	11.96	acidic
pKa5	13.08	acidic
pKa6	13.93	acidic
pKa7	9.41	Basic
pKa8	7.96	Basic
pKa9	7.31	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4024922	VUID
N0000171604	NUI
D01079	KEGG_DRUG
4024922	VANDF
C1260298	UMLSCUI
CHEBI:142708	CHEBI
T1C	PDB_CHEM_ID
CHEMBL376140	ChEMBL_ID
D000078304	MESH_DESCRIPTOR_UI
DB00560	DRUGBANK_ID
10929	IUPHAR_LIGAND_ID
C087533	MESH_SUPPLEMENTAL_RECORD_UI
8115	INN_ID
70JE2N95KR	UNII
54686904	PUBCHEM_CID
384455	RXNORM
20166	MMSL
230306	MMSL
69774	MMSL
d05537	MMSL
010833	NDDF
418313005	SNOMEDCT_US
418631002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Tygacil	HUMAN PRESCRIPTION DRUG LABEL	1	0008-4990	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	NDA	33 sections
Tygacil	HUMAN PRESCRIPTION DRUG LABEL	1	0008-4994	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	NDA	30 sections
Tigecycline	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3481	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	26 sections
Tigecycline	Human Prescription Drug Label	1	55150-228	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	28 sections
Tigecycline	HUMAN PRESCRIPTION DRUG LABEL	1	60505-6098	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	27 sections
Tigecycline	HUMAN PRESCRIPTION DRUG LABEL	1	70121-1647	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	NDA	22 sections
Tigecycline	HUMAN PRESCRIPTION DRUG LABEL	1	71288-019	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections
Tigecycline	HUMAN PRESCRIPTION DRUG LABEL	1	71288-019	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	50 mg	INTRAVENOUS	ANDA	30 sections

Ask DrugCentral

Try a sample question

tigecycline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: